NASDAQ · Biotechnology

BriaCell Therapeutics Corp. (BCTXW) Stock

$0.00 NASDAQ: BCTXW Healthcare

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, currently in Phase 3, dedicated to revolutionizing cancer treatment through its innovative cellular immunotherapies.

Valuation

MetricValue
Price$0.00
Market Cap$1695
P/E Ratio0.00
P/B Ratio0.00
P/S Ratio0.00
EPS (TTM)$-62.95
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-444.07%
ROA-161.64%
ROCE-71.22%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio3.42

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-7.0M$-15.0M$-23.0M$-33.0M$-28.0M
Net Profit$-14.0M$-27.0M$-20.0M$-5.0M$-27.0M
EPS$-467.51$-259.50$-195.00$-43.68$-62.95
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$58.0M$43.0M$27.0M$6.0M$22.0M
Total Liabilities$30.0M$32.0M$31.0M$9.0M$4.0M
Cash$57.0M$41.0M$21.0M$1.0M$11.0M
Borrowings$0$0$0$0$0

Latest News

Constellation Brands Shareholders Approve Directors, Pay and Incentive Plan at Annual Meeting MarketBeat · Jul 23, 2026 ITC Infotech and Google Cloud Join Hands to Scale Enterprise Agentic Transformation and AI Innovation Business Wire · Jul 23, 2026 Reo.Dev Bags $11.3M Series A to Scale Across the US ACCESS Newswire · Jul 23, 2026 High-Yield and High-Growth? This Energy Stock Backs Its 3.7%-Yielding Dividend With Booming AI-Driven Gas Demand. Motley Fool · Jul 23, 2026 eSign.AI Showcases AI-Native Electronic Signature Platform & VeriAgent.AI at WAIC 2026 PR Newswire · Jul 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-8.0M$-12.0M$-24.0M$-24.0M$-29.0M
Investing Cash Flow$0$0$0$-1.0M$-8.0M
Financing Cash Flow$14.0M$-4.0M$0$0$0
Net Cash Flow$57.0M$-16.0M$-20.0M$-20.0M$10.0M
Free Cash Flow$-8.0M$-12.0M$-24.0M$-25.0M$-29.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.66
FCF Yield-1453330.74%
Quick Ratio7.07
Interest Coverage452.26
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Institutional HolderSharesReport Date
Susquehanna International Group, LLP67,1112025-12-31
L1 Global Manager Pty Ltd7,0002025-12-31
Royal Bank of Canada2252025-12-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CELUCelularity Inc. $0.75 +0.13% -0.20 $21.74M 0.00%
KTTA $0.45 -2.17% -0.25 $3.35M 0.00%
LIXT $7.21 -6.00% -5.30 $89.11M 0.00%
NUWE $1.99 -2.93% -0.04 $724947 0.00%
OCEAOcean Biomedical, Inc. $0.00 — 0.00 $59318 0.00%

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, currently in Phase 3, dedicated to revolutionizing cancer treatment through its innovative cellular immunotherapies. Its flagship product, Bria-IMT, is currently undergoing a pivotal Phase 3 clinical trial for advanced breast cancer, where it's being evaluated in combination with an immune checkpoint inhibitor. Beyond this lead candidate, the company is also advancing the development of personalized, off-the-shelf treatments designed to combat breast, prostate, and various other forms of cancer. Furthermore, BriaCell maintains a strategic partnership with Incyte Corporation, focused on further evaluating Bria-IMT in combination therapies. The company's operations are headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp. (BCTXW) stock trades at $0.00 with a market capitalization of $1695. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, BriaCell Therapeutics Corp. generates a return on equity (ROE) of -444.07%, return on capital employed of -71.22%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: briacell.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides